DEA scheduling

DEA Schedules. Drugs under jurisdiction of the Controlled Substances Act are divided into five schedules based on their potential for abuse and physical and psychological dependence. All controlled substances listed in Drug Facts and ComparisondE) are identified by schedule as follows ... 

Security issues include the control of DEA scheduled compounds. For the less controlled substances, locked cages provide sufficient security however, the... 

There is increasing concern over the street abuse of dextromethorphan, which is available in a variety of products. There have been a few reports of abuse and a handful of case reports of overdose and death. Nevertheless, dextromethorphan was specifically left out of the Controlled Substances Act (CSA) of 1970 and has not been added to the Drug Enforcement Administration (DEA) scheduling process despite these reports. This decision was made because dextromethorphan is not considered a narcotic and is generally thought to have a low addiction potential. However, the DEA is monitoring dextromethorphan and may add it to its list of controlled substances at some point in the future. 

When methaqualone first entered the U.S. market in the mid-sixties, it was classified as a Schedule V drug by the U.S. Drug Enforcement Agency (DEA). Schedule V... 

All are Drug Enforcement Administration (DEA) Schedule II narcotics, indicating the highest risk of tolerance and dependence (addiction). 

Strike has also been poking around the DEA and is getting the distinct impression that they will very soon reschedule sassafras oil as schedule I. Then one won t be able to get it at all without a permit or some serious deception. 

Takeda s melatonin (MT1/MT2) receptor agonist ramelteon (11) was approved and launched in 2005 in the U.S., indicated for the treatment of primary insomnia characterized by difficulty with sleep onset. It is the first prescription medication for insomnia with a novel mechanism of action to reach the US market in 35 years. It is also the first and only prescription sleep medication that has not exhibited potential for abuse and dependence, and as such is not designated as a scheduled substance by the DEA. Moreover, ramelteon was also filed in late March 2007 in E.U. for primary insomnia. 

Concerns about the use of ketamine as a human anesthetic began to arise in the early 1970s, however, when some patients reported having unsettling psychedelic experiences. Over the next two decades, the use of ketamine in surgical procedures in the United States decreased until, in 1999, the DEA listed ketamine as a Schedule III drug. It is now used almost exclusively in the United States for veterinary procedures, although it can be used for certain specialized procedures with humans. 

GHB has met a somewhat different fate in the United States, however. In 1990, the FDA banned the sale of the drug in the United States because of its concerns over possible risks to human health. In view of the generally positive research on the drug s use, the sci-entihc basis of the FDA s decision was not entirely clear at the time to some observers. In any case, the drug s legal status was clarified in 2000 when the DEA classihed it as a Schedule I drug under the Controlled Substances Act. 

Some analogs of GHB are also available on the street. These include gamma hydroxyvalerate (GHV), gamma butyrolactone (GBL), gamma valerolactone (GVL), and 1,4-hutanediol. The last three of these drugs all metabolize into GHB, so they have effects similar to those of GHB itself. None of the four analogs of GHB has yet been classified by the DEA in any one of the five schedules defined by the Controlled Substances Act. 

Prescriptions Prescriptions for controlled substances must be written in ink and include the following Date name and address of the patient name, address, and DEA number of the physician. Oral prescriptions must be promptly committed to writing. Controlled substance prescriptions may not be dispensed or refilled more than 6 months after the date issued or be refilled more than 5 times. A written prescription signed by the physician is required for schedule II drugs. In case of emergency, oral prescriptions for schedule II substances may be filled however, the physician must provide a signed prescription within 72 hours. Schedule II prescriptions cannot be refilled. A triplicate order form is necessary for the transfer of controlled substances in schedule II. Forms are available for the individual prescriber at no charge from the DEA. 

Medications under the control of the US Drug Enforcement Agency (Schedules I-V controlled substances) are indicated by the symbol (C). Most medications are uncontrolled" and do not require a DEA prescriber number on the prescription. The following is a general description for the schedules of DEA-controlled substances ... 

Brand Name(s) Xanax, Niravam, Xanax, XanaxXR Chemical Class Benzodiazepine DEA Class Schedule IV... 

Chemical Class Opiate derivative thebaine derivative DEA Class Schedule V... 

Chemical Class Opiate derivative phenylpiperidine derivative DEA Class Schedule II... 

---